CTCTRAP

Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients

 Coordinatore UNIVERSITEIT TWENTE 

 Organization address address: DRIENERLOLAAN 5
city: ENSCHEDE
postcode: 7522 NB

contact info
Titolo: Mr.
Nome: Ferdinand
Cognome: Damhuis
Email: send email
Telefono: +31 53 4894019
Fax: +31 53 4894841

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 8˙321˙935 €
 EC contributo 6˙000˙000 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2012-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-09-01   -   2016-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITEIT TWENTE

 Organization address address: DRIENERLOLAAN 5
city: ENSCHEDE
postcode: 7522 NB

contact info
Titolo: Mr.
Nome: Ferdinand
Cognome: Damhuis
Email: send email
Telefono: +31 53 4894019
Fax: +31 53 4894841

NL (ENSCHEDE) coordinator 970˙000.00
2    LEUKOCARE AG

 Organization address address: AM KLOPFERSPITZ 19
city: MARTINSRIED
postcode: 82152

contact info
Titolo: Prof.
Nome: Martin
Cognome: Scholz
Email: send email
Telefono: +49 89 780166517

DE (MARTINSRIED) participant 810˙000.00
3    INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL

 Organization address address: Old Brompton Road 123
city: LONDON
postcode: SW7 3RP

contact info
Titolo: Ms.
Nome: Lydia
Cognome: Turner
Email: send email
Telefono: +44 207 1535274
Fax: +44 208 6427979

UK (LONDON) participant 636˙250.00
4    ISTITUTO ONCOLOGICO VENETO

 Organization address address: VIA GATTAMELAYA 64
city: PADOVA
postcode: 35128

contact info
Titolo: Dr.
Nome: Rita
Cognome: Zamarchi
Email: send email
Telefono: +39 049 821 5873
Fax: +39 049 8215646

IT (PADOVA) participant 636˙250.00
5    AQUAMARIJN MICRO FILTRATION BV

 Organization address address: BERKELKADE 11
city: ZUTPHEN
postcode: 7201JE

contact info
Titolo: Dr.
Nome: Arjan
Cognome: Tibbe
Email: send email
Telefono: +31 6 14773442
Fax: +31 53 4893511

NL (ZUTPHEN) participant 610˙000.00
6    ASPER BIOTECH AS

 Organization address address: VAKSALI 17A
city: TARTU
postcode: 50410

contact info
Titolo: Dr.
Nome: Anu
Cognome: Aaspõllu
Email: send email
Telefono: +37 252 11586

EE (TARTU) participant 610˙000.00
7    HEINRICH-HEINE-UNIVERSITAET DUESSELDORF

 Organization address address: UNIVERSITAETSSTRASSE 1
city: DUSSELDORF
postcode: 40225

contact info
Nome: Doris
Cognome: Neubert
Email: send email
Telefono: +49 211 81 19586
Fax: +49 211 81 18576

DE (DUSSELDORF) participant 386˙250.00
8    INSTITUT GUSTAVE ROUSSY

 Organization address address: Rue Camille Desmoulins 39
city: VILLEJUIF
postcode: 94805

contact info
Titolo: Mr.
Nome: Arnauld
Cognome: Forest
Email: send email
Telefono: 33142116604
Fax: 33142116150

FR (VILLEJUIF) participant 386˙250.00
9    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

 Organization address address: GESCHWISTER SCHOLL PLATZ 1
city: MUENCHEN
postcode: 80539

contact info
Titolo: Dr.
Nome: Brigitte
Cognome: Rack
Email: send email
Telefono: +49 89 51604170
Fax: +49 89 51604715

DE (MUENCHEN) participant 386˙250.00
10    MAGYAR TUDOMANYOS AKADEMIA SZEGEDI BIOLOGIAI KOZPONTJA

 Organization address address: Temesvari krt. 62
city: SZEGED
postcode: 6701

contact info
Titolo: Dr.
Nome: Csaba
Cognome: Vizler
Email: send email
Telefono: +36 62599649

HU (SZEGED) participant 383˙750.00
11    ACZON SRL

 Organization address address: VIA LAVINO 265 D
city: MONTE SAN PIETRO BO
postcode: 40050

contact info
Titolo: Dr.
Nome: Alfredo
Cognome: Ventola
Email: send email
Telefono: +39 51 6759711
Fax: +39 51 6759799

IT (MONTE SAN PIETRO BO) participant 185˙000.00
12    EBERHARD KARLS UNIVERSITAET TUEBINGEN

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Prof.
Nome: Tanja
Cognome: Fehm
Email: send email
Telefono: +49 7071 2982211

DE (TUEBINGEN) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

blood    risk    ctcapheresis    metastatic    treatment    metastasis    characterization    cancer    optimal    patients    ctc    course    therapeutic    cells    tumor    disease    biopsy    peripheral    ta   

 Obiettivo del progetto (Objective)

'Chemotherapy is slowly being supplemented by a new generation of drugs that recognize specific targets in or on cancer cells and has proven to be more effective with markedly fewer side effects. During the course of the disease alternative oncogenic signaling pathways take over inevitably leading to drug resistance. As a consequence renewed tumor analysis is required to redefine the optimal treatment regiment. However a biopsy can frequently not be obtained without risk and or discomfort to the patient. Circulating tumor cells (CTC) may circumvent this problem. CTC refer to cells that detach from a primary tumor or metastatic site, circulate in the peripheral blood and may form metastasis. CTC represent a 'liquid biopsy' that can be used to tailor treatment for individual patients. CTC are however rare and can only be obtained for further characterization in a small fraction of patients. In the CTCtrap consortium universities, research institutions and SMEs are linked in a common effort, starting from the simple, but innovative view of using Therapeutic Apheresis (TA), as a way to collect CTC from peripheral blood in cancer patients. A new TA column will be developed to capture CTC and then reintroduce the blood devoid of tumor cells back into the body with the promise to obtain CTC in all patients at risk for recurrence or diagnosed with metastatic disease. The molecular characterization of these CTC is expected to gather new knowledge on metastasis' mechanism, provide a risk assessment and the optimal therapy choice during the course of the disease of cancer patients. The new knowledge on CTC heterogeneity within cancer type and within individuals will allow for the tuning of CTCapheresis to specific cancer types. Prospective pilot studies will be setup to investigate the feasibility of the CTCapheresis in the clinic and their potential therapeutic benefit. Success of CTCapheresis will lead to a radical change in the diagnosis and treatment of solid tumors.'

Altri progetti dello stesso programma (FP7-HEALTH)

FLUNIVAC (2013)

InFLUenza virus UNIVersal VACcine development program

Read More  

DESIRE (2013)

"Development and Epilepsy - Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat Epilepsy"

Read More  

SETTREND (2010)

"Schistosoma Epigenetics - Targets, Regulation, New Drugs"

Read More